Shape Biopharmaceuticals develops SHAPEnano particles, a class of structurally defined, 3D-optimized engineered nanomedicines designed to elicit patients' own immune systems to produce therapeutic antibodies. The approach aims to improve accessibility and affordability of immunotherapies by reducing dosing to two to three doses per year, lowering risk of anti-drug antibodies, and delivering substantial cost savings. The company will use CHF 150,000 from Venture Kick to accelerate business and product development and progress strategic initiatives toward delivering treatments. CEO Arin Ghasparian and CSO Armando Zuniga are repeat biotech entrepreneurs with experience taking novel vaccine and drug delivery technologies from concept to clinic. Shape positions its technology against a growing chronic disease burden and an expanding immunotherapy market, which the article cites as a CHF 173 billion market by 2030 and projected global chronic disease costs exceeding CHF 40 trillion by 2030.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2024